Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Lack of follow-up finance in 2011 for European biotech

This article was originally published in Scrip

Executive Summary

In 2011 so far, almost as many European biotechnology companies have received seed or series A venture finance as their counterparts in North America. However, the early sums raised by European firms are 30-40% less than those in North America. Furthermore, and perhaps more importantly, the number of later finance rounds in Europe is only just over a quarter of that in the US and Canada, suggesting that Europe’s emergent industry must continue to learn to live without a fully supportive financial infrastructure.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts